University of Central Florida

STARS
Electronic Theses and Dissertations, 2004-2019
2007

A Member Of The Novel Fikk Family Of Plasmodium Falciparum
Putative Protein Kinases Exhibits Diacylglycerol Kinase Activity
And Is Exported To The Host Erythrocyte
David Floyd Curtis
University of Central Florida

Part of the Microbiology Commons, Molecular Biology Commons, and the Virus Diseases Commons

Find similar works at: https://stars.library.ucf.edu/etd
University of Central Florida Libraries http://library.ucf.edu
This Masters Thesis (Open Access) is brought to you for free and open access by STARS. It has been accepted for
inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more
information, please contact STARS@ucf.edu.

STARS Citation
Curtis, David Floyd, "A Member Of The Novel Fikk Family Of Plasmodium Falciparum Putative Protein
Kinases Exhibits Diacylglycerol Kinase Activity And Is Exported To The Host Erythrocyte" (2007).
Electronic Theses and Dissertations, 2004-2019. 3130.
https://stars.library.ucf.edu/etd/3130

A MEMBER OF THE NOVEL FIKK FAMILY OF PLASMODIUM
FALCIPARUM PUTATIVE PROTEIN KINASES EXHIBITS
DIACYLGLYCEROL KINASE ACTIVITY AND IS EXPORTED TO THE HOST
ERYTHROCYTE

by
DAVID F. CURTIS
B.S. University of Central Florida, 1996

A thesis submitted in partial fulfillment of the requirements
for the degree of Master of Science
in the Department of Microbiology and Molecular Biology
in the Burnett School of Biomedical Sciences
in the College of Medicine
at the University of Central Florida
Orlando, Florida

Fall Term
2007

© 2007 David F. Curtis

ii

ABSTRACT

Plasmodium falciparum is one of four species known to cause malaria in humans and
is the species that is associated with the most virulent form of the disease. Malaria causes
nearly two million deaths each year, many of these occurring among children in underdeveloped countries of the world. One reason for this is the prevalence of drug resistant
strains of malaria that mitigate the efficacy of existing drugs. Hence, the identification of
a new generation of pharmacological agents for malaria is extremely urgent.
The recent identification of a group of novel protein kinases within the Plasmodium
falciparum genome has provided researchers with a basis for what many hope to be new
potential drug targets for malaria. Identified within the Plasmodium genome and a few
select apicomplexans, these novel proteins have been predicted to be protein kinases
based solely on certain sequence features shared with other eukaryotic protein kinases
(ePKs). However, to date, no significant studies to determine the function of these novel
kinases have been performed. Termed FIKKs, these proteins all possess a non-conserved
N-terminal sequence that contains a Plasmodium export element (Pexel) which may
target the proteins for export from the parasite and a conserved C-terminal catalytic
domain containing a FIKK sequence common to all twenty members of this family.
We analyzed the localization of one of the FIKK proteins, FIKK11, encoded by the
PF11_0510 locus, during intraerythrocyte differentiation of P. falciparum by Western
blot analysis and indirect immunofluorescence assay.

Western blot analysis

demonstrated that FIKK 11 is expressed within the parasite at all stages of its erythrocytic
life cycle with its highest expression occurring during the schizont stage.
iii

Immunofluorescence assays showed that this protein is exported from the Plasmodium
parasite into the host erythrocyte cytosol which is consistent with studies on other
Plasmodium proteins that also have the Pexel motif.
To determine the enzymatic activity of FIKK11, we overexpressed the recombinant
protein in E. coli and then purified it. However, no protein kinase activity was detected
using several commonly used protein kinase substrates including histone H1, myelin
basic protein, or dephosphorylated casein. We also did not detect any kinase activity of
the native enzyme using pull-down assays of the Plasmodium falciparum cell extract
against those same substrates. In addition, kinase substrate peptide array analysis of
FIKK11 showed no evidence of protein kinase activity either for FIKK11. Interestingly,
however, we were able to detect some kinase activity using the recombinant protein alone
with no substrate.
The lack of the glycine triad within subdomain I of these FIKK kinases as compared
with most traditional eukaryotic protein kinases may explain why we were unable to find
any interactions between FIKK11 and other commonly protein kinase substrates. Of
interest was the observation that the protein reproducibly exhibited what appeared to be
an autophosphorylation activity when using the standard protein kinase assay. Further
analyses, however, showed that FIKK11 actually possesses diacylglycerol kinase activity
utilizing 1-Stearoyl-2-arachidonoyl-sn-glycerol as a substrate. This is the first evidence
of diacylglycerol kinase activity in Plasmodium falciparum.

Because FIKK11 is

exported into the host cell and is localized on the erythrocyte membrane, its enzymatic
activity may potentially have relevance in the pathophysiology of the disease.
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CHAPTER ONE: INTRODUCTION

Background

The genus, Plasmodium, is the causative agent of malaria, a diesease that
threatens approximately 40% of the world’s population (Breman, 2001). The
majority of the cases of malaria are found in the tropical and subtropical regions
of the world and this disease results in 300 to 500 million clinical cases per year
with one to three million of those cases leading to death (Breman, 2001). Of the
known species of Plasmodium, four have been identified as being directly
responsible for infection of the human host: P. falciparum, P. vivax, P. malariae,
and P. ovale. Among these four species, Plasmodium falciparum is responsible
for the majority of the clinical cases of malaria and is, consequently, the most
lethal.
The word malaria comes from the Italian term mal’aria that translates into
“bad air”. Its name comes from the belief among ancient cultures that the fevers
common among the disease state were caused by breathing bad air within certain
areas that had become inundated with standing, stagnant water. In 1716, the
Italian physician Giovanni Maria Lancisi saw black pigmentation of brain and
spleen samples from patients suffering from malarial symptoms.

The first

observation of the parasite itself, however, came in 1847 when the German
scientist Heinrich Meckel observed black-pigmented granules in the blood and
spleen of a deceased, diseased patient.
1

It wasn’t until 1879 that Afanasiev

suggested that the disease state itself was actually caused by the granules. In
1880, Louis Alphonse Laveran identified the parasite in human erythrocytes and
described both trophozoite and schizont stages of the parasite. By 1897, the
combined work of Patrick Manson and Ronald Ross confirmed that the parasite
was transmitted to its human host via the mosquito vector.
The first actual treatment for malaria came in 1820 with the discovery of
quinine, an alkaloid from the bark of the Cinchona ledgeriana tree. As the supply
of quinine became limited during World War II, and soldiers were exposed to
potential malaria on tropical and subtropical battlefields, there was an increase in
research for synthetic antimalarial drugs.

This prompted the discovery

chloroquine in 1934 (Greenwood, 1995; Schmidt and Roberts, 1989).
Chloroquine has remained one of the most commonly prescribed treatments for
malaria, partially because of its low production costs. The last several decades,
however, have seen an alarming increase in the number of chloroquine-resistant
cases throughout the world. The causes for this increase have been attributed to
incorrect drug dosing, patient noncompliance with the duration of their treatment,
poor drug quality and misdiagnosis (Bloland, 2001).

Because most other

antimalarial drugs are chemically related to chloroquine, many show drugresistance to strains of malaria within a few years of release.

This rise in

resistance to antimalarial drugs makes the search for new, novel antimalarial
agents more critical than ever. By having a better understanding of just how
cellular functions within the Plasmodium parasite are regulated, this search for a
consistent, effective treatment will have a better chance of reaching fruition.
2

Plasmodium falciparum Life Cycle

The life cycle of the malaria parasite is quite complex as can be seen in
fig. 1. The Anopheles mosquito acts as the vector for the infection of a human
host with Plasmodium falciparum. Infection of the human host begins when the
mosquito delivers sporozoites into the bloodstream which then travel to the liver
and establish an infection inside the host’s hepatocytes.

Here they undergo

multiple rounds of multiplication called exo-erythrocytic schizogony that results
in the formation of thousands of merozoites. These merozoites are then freed and
infect the host’s erythrocytes where they undergo additional schizogony resulting
in the actual pathogenesis of the malaria parasite. Some of the merozoites may
arrest their cell cycle and develop into male or female gametocytes that may then
infect the mosquito vector should a subsequent bite occur.

Once inside the

mosquito, these gametocytes become gametes that then fuse to form a zygote.
The zygote undergoes sporogony leading to the production of sporozoites. These
sporozoites accumulate in the salivary glands of the where they await infection of
a new human host.

3

Figure 1. Life Cycle of the Plasmodium falciparum Parasite
Image borrowed from http://www.cdc.gov/malaria/images/graphs/malaria_LifeCycle.gif
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A Novel Set of Plasmodium falciparum Kinases

With the increase in resistance of malaria to chloroquine and other
chemotherapeutic agents, researchers are exploring new drug targets as potential
agents in the fight against malaria. An interesting trend is the examination of
protein kinases as chemotherapeutic agents. A well-documented example of this
is the drug Gleevec produced by Novartis. This protein kinase inhibitor is used as
a treatment for various forms of cancer since protein kinases are an important
family of proteins that regulate diverse cellular activities.
Sequencing of the P. falciparum genome (Gardner et al., 2002) has led to
the identification of the complete repertoire of parasite protein kinases based on
homology searches (Ward et al., 2004). These searches, however, have only
identified 65 protein kinases within the malaria genome which seems quite low
compared to Saccharomyces cerevisiae which has a similar number of total genes
but encodes nearly twice the number of protein kinases. The implication is that
malaria protein kinases may possess more complex and novel cellular functions
when compared to other eukaryotic kinomes. Of the Plasmodium falciparum
protein kinases identified, the presence of a novel family of 20 putative protein
kinases is particularly noteworthy (Schneider and Mercereau-Puijalon, 2005:
Ward et al., 2004). This family of kinases is termed FIKK for the presence of a
conserved amino acid sequence motif: phenylalanine-isoleucine-lysine-lysine
(Ward et al., 2004). All family members contain a non-conserved N-terminal
domain and a conserved C-terminal kinase domain (Fig. 2). Although FIKK

5

orthologues have been identified in other Plasmodium species and certain
apicomplexans (Toxoplasma gondii and Cryptosporidium parvum), only P.
falciparum and P. reichenowi exhibit extensive gene amplification with twenty
distinct kinases found in the former and six found in the latter.

6

Figure 2. The Plasmodium falciparum FIKK Gene Family
The black bar shows the C-terminal kinase domain; the white bar shows the polymorphic
region within the kinase domain; the shaded bar within the kinase domain shows the
repeat sequence; the arrow delineates the exon borders; the asterisk shows the location of
the Pexel motif; the shaded bar in the N-terminal region shows the signal sequence; g
represents gene that are annotated; R is ring stage; T is trophozoite stage; Sc is schizont
stage; Mz is merozoite stage; Sp is sporozoite stage. Figure was taken from Schneider
and Mercereau-Puijalon, 2005.
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FIKKs as Potential Protein Kinases

Sequence comparisons of conventional eukaryotic protein kinases and the
FIKK kinases show that the FIKKs possess many the conserved residues believed
to be important for catalytic activity with the exception of the glycine triad in
subdomain I. Although this sequence (GxGxxG) helps to anchor ATP or GTP in
the catalytic cleft, the phosphotransfer ability of a kinase is not entirely dependent
on it. A third of human protein kinases do not contain the third glycine residue of
the triad and the first residue is absent in about 11% of the kinases (Kostich et al.,
2002). S. pombe MIK1 tyrosine kinase that phosphorylates p34cdc2 lacks all
three residues of the triad (Lee et al., 1994). P. falciparum PfPK7 kinase contains
only the second glycine residue of the triad (Dorin et al., 2005).

Though

catalytically inactive proteins that maintain a kinase fold are not uncommon, these
“pseudokinases” lack selective pressure to maintain residues directly involved in
catalysis and possess amino acid substitutions in one or more of the conserved
catalytic residues analogous to Lys72, Asp166, or Asp184 (mammalian PKA
numbering).
The invariant lysine in subdomain II that is involved in the orientation of
α and β phosphate groups of ATP appears in the FIKK signature motif of this
novel family of kinases. Presence of motifs close to HRDLKPxN (HLDxxPxN)
and APE (PPE) in subdomains VIB and VIII, respectively, suggests that FIKK
family members may function as kinases. The aspartic acid in the HRDLKPxN
consensus sequence acts as a general base during catalysis to facilitate phosphate
8

transfer.

The aspartic acid of the conserved DFG motif (Dxx in FIKKs)

coordinates the divalent cation that bridges with the β- and γ-phosphates of the
purine nucleotide. The invariant arginine residue in subdomain XI that stabilizes
the large carboxy-terminal lobe is present in FIKKs. Because each of these
residues is absolutely conserved among all members of the FIKK family (Fig. 3),
it is expected that they are likely to function as protein kinases. The FIKK family
exhibits 38-64% identity among the paralogs within the presumed catalytic
domain (Schneider and Mercereau-Puijalon, 2005).
In spite of significant conservation of residues that are important for
catalytic activity, the absence of the defined glycine triad calls into question their
roles as authentic protein kinases. Therefore it is important to confirm that these
proteins are in fact functional proteins.

9

Figure 3. Sequence Alignment of Members of the FIKK Kinase Family with PfPK5
The Sequence alignment was done by CLUSTALW algorithm. Conserved residues in
eukaryotic protein kinases are indicated by a red asterisk.
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The N-terminal domain is not conserved among the paralogs and this
region contains a stretch of hydrophobic residues corresponding to a predicted
trans-membrane or signal sequence domain (Schneider and Mercereau-Puijalon,
2005). A recently described host-targeting signal motif, RxSRILAExxx (Hiller et
al., 2004) is present in six of the FIKK paralogs while the Plasmodium export
element RxLx(D, E, Q) (Marti et al., 2004) can be detected in all FIKK paralogs
downstream of the signal sequence. Because HT/Pexel motifs have been shown
to mediate export of proteins beyond the parasitophorous vacuole into the
erythrocyte cytoplasm (Hiller et al., 2004; Marti et al., 2004), it is expected that
the FIKK kinases are also trafficked to the erythrocyte.

Goal of the Work Within this Thesis

The distant relationship between the FIKK kinases and the more typical
eukaryotic protein kinases generates optimism that it may be possible to engineer
selective inhibitors targeting this novel family of kinases.

However, clear

physiological and/or cell biological data are needed to implicate FIKK kinases as
an attractive target for drug therapy.

Therefore, we decided to characterize

FIKK11, a member of the FIKK family.

The goal was two-fold: first, to

determine whether selected members of the FIKK kinase family are indeed
expressed in vivo within the Plasmodium falciparum parasite and whether the
proteins are exported into the host erythrocyte as is implicated by the presence of
an HT/Pexel motif within these proteins. Secondly, to identify the potential
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function of selected members of the FIKK kinase family by assessing whether
they are truly protein kinases as has been speculated.
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CHAPTER TWO: METHODOLOGY

Cell Culture

Plasmodium falciparum strain 3D7 was maintained n 100mm tissue
culture dishes using human A+ red blood cells. The culture was incubated at
37oC with a 5% carbon dioxide/95% air mixture. The culture medium used was
RP10S consisting of RPMI-1640 (MOD.) supplemented with 25mM HEPES,
0.2% dextrose, 0.15% hypoxanthine, 25µg/ml gentamycin, and 10% human
serum or 0.5% Albumax. Collection of the culture for parasite isolation involves
resuspending the cells and transferring them to a 50ml conical tube. Release of
the parasite from the red blood cell was achieved by treating the suspension with
0.1% saponin followed by incubating the mixture at room temperature for five
minutes. Afterwards, the mixture was centrifuged at 4000rpm for seven minutes
at 4oC to separate the parasites from the red blood cell lysate. The supernatant
was then removed and the pellet was resuspended in 1X PBS. The pellet was
washed once with PBS and was subsequently stored at -80oC until needed. In
order to perform stage-specific analyses on the parasite, the cell culture was
synchronized by treatment with 5% D-sorbitol for 15 minutes at 37oC. The Dsorbitol treatment preferentially selects in the parasites in the ring stage (Lambros
and Vanderberg, 1979). The D-sorbitol was thoroughly removed from the culture
using several washes with RPMI-1640 and the culture was resuspended in RP10S
media as described above and plated again onto tissue culture plates. The culture
13

was then incubated as above until the desired stage was reached and then
harvested as above at either six or eight hour intervals to assure that ring,
trophozoite, and schizont stages were equally represented.

Plasmodium RNA Extraction

The asynchronous Plasmodium falciparum 3D7 culture was harvested as
previously mentioned. After the final PBS wash, the pellet was treated with 3ml
RNAgents Denaturing Solution (Promega) and stored at -80oC until needed. The
pellet was later thawed on ice and 600µl 2M sodium acetate (pH 4) was added.
This mixture was then treated with 6ml Phenol:Chlorophorm:Isoamyl Alcohol
and incubated on ice for fifteen minutes. The entire mixture was then transferred
to a DEPC-treated centrifuge tube and centrifuged at 10000g for twenty minutes
at 4oC. The upper, aqueous phase was transferred to a clean DEPC-treated tube
and an equal volume of isopropanol was added and allowed to incubate at -20oC
overnight. The mixture was centrifuged as above and the supernatant removed
from the RNA pellet. 2.5ml Denaturing Solution was added and the pellet was
resuspended.

Next, 2.5ml isopropanol was added and incubated at -20oC

overnight. The mixture was centrifuged again as above and the supernatant was
removed.

The pellet was then washed with 1ml ice-cold 75% ethanol and

centrifuged as above. The supernatant was discarded and the pellet was air-dried
one hour. The RNA pellet was resuspended in 100µl nuclease-free water and
transferred to RNase-free, screw-capped microcentrifuge tubes and stored at 14

80oC until needed. The purity and integrity of the RNA sample was verified by
running on a 1% formaldehyde denaturing gel for three hours at 75V using 1X
MOPS buffer before it was accepted for use in RT-PCR.

cDNA Synthesis by Reverse Transcription

RNA obtained from the asynchronous Plasmodium falciparum 3D7
isolates as outlined above was used to synthesize cDNA for cloning. PlasmoDB
was searched for valid sequences for PF11_0510 (FIKK 11) and PF10_0160
(FIKK 10.1), two putative Plasmodium falciparum protein kinases belonging to
the FIKK kinase family. Based on these sequences, full length and fragment
genes containing only the C-terminal kinase domain were then analyzed and the
appropriate primers designed to obtain the desired sequence.

Invitrogen

synthesized the primers for cloning the open reading frames into the pET43.1
Ek/LIC vector. The RT-PCR reaction was carried out using the ProStar RT-PCR
Kit (Stratagene). Table 1 lists the primers used cloning into pET43.1 and Table 2
shows the actual RT-PCR conditions used for cloning.

15

Table 1. Primer Sequences Used for Cloning into the pET43 Vector
Primers were designed using PlasmoDB to determine the consensus sequence for priemr
creation. The oligo-(DT) primers were ordered through Invitrogen.

Construct

Length

FIKK10.1

1.227 kb

FIKK11

Direction

Primer Sequence

Tm

Forward

GAGGAGAAGCCCGGTTTACATTTTAGAAAACCACCA

50

Reverse

GACGACGACAAGATGTGGAATTTAGGTAAAAAATC

50

Forward

GACGACGACAAGATGTGGATAGAGGGTTATAAAT

50

Reverse

GAGGAGAAGCCCGGTTTATTCTTTCCACCATGG

50

1.218 kb
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Table 2. PCR Conditions for Amplification of FIKK10.1 and FIKK11

Elongation

Template

35 Cycles

Protein

5 Cycles

FIKK10.1

1ug
RT

95

30

50

30

65

6

95

30

58

30

65

6

65

10

FIKK11

1ug
RT

95

30

50

30

65

6

95

30

58

30

65

6

65

10

Temp
(oC)

Time
(sec)

Temp
(oC)

Time
(sec)

Temp
(oC)

Time
(min)

Temp
(oC)

Time
(sec)

Temp
(oC)

Time
(sec)

Temp
(oC)

Time
(min)

Temp
(oC)

Time
(min)
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cDNA Cloning

After RT-PCR, 5µl of the PCR sample was run on a 0.8% agarose gel to
verify the amplification. The PCR products were purified using the QIAquick
Purification Kit (Qiagen) and the purified samples were run again on a 0.8%
agarose gel to verify the recovery of the product and to determine the
concentration of the samples. Approximately 0.2pmol of purified PCR product
was then treated with T4 DNA Polymerase mix consisting of T4 DNA
Polymerase, 25mM dATP, 100mM DTT, and 10X T4 DNA Polymerase Buffer
for thirty minutes at room temperature. The product was cloned into the pET43.1
Ek/LIC vector utilizing the LIC sequence and then transformed into NovaBlue
supercompetent Escherichia coli cells by heat-shock treatment as per the
manufacturer’s protocol (Novagen). SOC media was added to the heat-shocked
cells and the mixture incubated at 37oC for ninety minutes with agitation before
being plated onto LB agar plates containing Kanamycin (50µg/ml). The plates
were incubated overnight at 37oC. The following day, isolated colonies were
chosen for inoculation into 5ml LB broth containing Kanamycin (50µg/ml) and
incubated at 37oC overnight with agitation. The cultures were then used to isolate
plasmid DNA using the QIAquick Spin Miniprep Kit (Qiagen).

18

DNA Sequencing

The isolated, digested inserts that corresponded to the correct size for the
given gene were further verified by sequencing performed at the University of
Florida DNA Sequencing Core facility using the T7 primer for forward sequences
and the SP6 primer for reverse sequences. The sequences were then analyzed and
verified using the DNAstar SeqMan software.

Protein Expression

The isolated plasmids were transformed into BL21 Codon+ DE3 RIPL
supercompetent Escherichia coli cells by heat-shock treatment and plated onto LB
agar with Kanamycin (50µg/ml). The plates were incubated overnight at 37oC
and colonies selected the next day for inoculation into 5ml LB with Kanamycin
(50µg/ml). These cultures were incubated overnight at 37oC with agitation. The
following day, the cultures were used to inoculate 195ml LB with Kanamycin
(50µg/ml) and incubated at 37oC until the OD600 reached 0.6. At that time 1mM
IPTG was added to induce expression of the desired protein and incubated at 27oC
for another 4 hours. Afterwards, the cultures were spun down at 6000rpm for
twenty minutes, the supernatant removed, and the pellet resuspended in 10ml
TALON Wash Buffer (50mM Sodium Phosphate pH 7, 300mM NaCl, and
protease inhibitors (Roche Mini Complete EDTA-free)).

19

TALON Affinity Purification

The resuspended pellet in TALON wash buffer was thawed on ice and
incubated for thirty minutes in the presence of 75µl Lysozyme to digest the cell
walls. The cell suspension was sonicated for seven cycles of twenty seconds (to
release the proteins. There was a rest of forty seconds between sonication cycles.
The sonicated lysate was centrifuged at 13000rpm for twenty minutes and the
clarified supernatant was added to pre-washed TALON beads (BD Bioscience).
The column was washed using 1X Wash Buffer (50mM Sodium Phosphate,
300mM NaCl, pH7) and non-bound proteins removed using 1X Extraction Buffer
(50mM Sodium Phosphate, 300mM NaCl, pH8).. The protein of interest was
eluted from the column using 1X Elution Buffer (50mM Sodium Phosphate,
300mM NaCl, 150mM Imidazole, pH7). After elution, the protein sample was
stored at -80oC until needed.

Protein Kinase Assay

To determine whether the purified proteins exhibited any protein kinase
activity, the proteins were assayed for protein kinase activity in a reaction
containing 0.1µCi of γ32P-ATP, 50µM “cold” ATP and the 5X kinase buffer
mixture (250mM Tris-HCl (pH 7.4), 50mM MgCl2, 10mM DTT, 200mM βGlycerophosphate, and 0.5mM Sodium Orthovanadate). Following incubation for
5 minutes, 0.5µg of the FIKK 11 protein was added and the reaction was allowed

20

to incubate for one additional hour at 30º C. At the end of this incubation period,
the reaction was stopped by addition of 0.5M EDTA.

10µl of the reaction

mixture was spotted onto Whatmann P81 filter discs and allowed to dry. The
unbound

32

P was removed with 3 washes with 1% phosphoric acid.

The

radioactivity present in the samples was measured using the Beckman scintillation
counter. The remaining reaction mixture was run on an SDS-PAGE gel and
stained to verify that the protein of interest was present. Additional kinase assays
were done in which the incubation time of protein in the presence of radioactive
ATP, buffer pH, and buffer ionic cofactors were varied.

Glycerol Kinase Assay

To determine whether FIKK 11 had any glycerol kinase activity, the
protein was incubated in the presence of glycerol and ATP using the oxidation of
NADH to determine whether the glycerol was utilized by the kinase. 2.5mM
ATP was incubated for five minutes in the presence of a reaction mixture (0.05M
Triethanolamine-HCl (pH 7.0), 2.5mM MgCl2, 20mM KCl, 0.1mM βMercaptoethanol, 0.2mM Phospho(enol)pyruvate, 0.2mM NADH, 2mM Glycerol,
5U/ml Pyruvate Kinase, and 5U/ml Lactate Dehydrogenase). Then 100ng of
FIKK 11 or a commercially available E. coli glycerol kinase was added and the
activity measured over the course of eight minutes using a Hewlett-Packard 8453
spectrophotometer to determine the decrease in absorbance of NADH at 340nm.
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The reaction velocity is measured in a coupled system with pyruvate kinase and
lactate dehydrogenase as follows:
Glycerol + ATP ' α-Glycerophosphate + ADP
ADP + PEP ' ATP + Pyruvate
Pyruvate + NADH + H+ ' Lactate + NAD+
One unit of glycerol kinase results in the oxidation of one µmol of NADH
per minute at 25oC and pH 8.9 and is measured using a spectrophotometer at
340nm over the course of 5-8 minutes.

Diacylglycerol Kinase Assay

To analyze whether FIKK 11 had any diacylglycerol kinase activity, the
protein was incubated in the presence of radioactive 32P ATP and a commercially
available diacylglyerol as described below and analyzed by thin layer
chromatography and phosphoimaging to determine activity. 250 µM Cardiolipin
and 500 µM 1-Stearoyl-2-arachindonoyl-sn-glycerol or 1,2-Dioleoyl-sn-glycerol
was dissolved in 1mM Sodium Desoxycholate. 1µg FIKK 11 or commercially
available E. coli diacylglycerol kinase was added to the lipid mixture along with a
reaction mixture (40mM Bis-Tris (pH 7.5), 5mM MgCl2, 0.1mM EDTA, 1mM
Spermine, 0.5mM DTT, and 0.02% Triton X-100) and incubated at room
temperature for five minutes. In addition, 30µM calcium was added in some
reactions to see if it had any impact on kinase activity. Then, 1mM ATP (with
5µCi radioactive 32P ATP) was added and the reaction allowed to incubate at
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room temperature for thirty minutes. The reaction was stopped by adding 750µl
chloroform/methanol (1:2) with 1% HCl. Next, 1ml of chloroform/methanol (1:1)
and 500µl 1M KCl with 0.2M phosphoric acid was added and the samples
vortexed and centrifuged at 2000rpm for five minutes. The lower phase was
transferred to a new reaction tube and the samples dried under a nitrogen stream.
The samples were then resuspended in 50µl chloroform/methanol (2:1) and
applied to TLC silica plates (EMD Chemicals). The plates were run using a
chloroform/acetone/methanol/acetic acid/water (40:15:14:12:8) mixture.

The

TLC Silica plate was then exposed BioMax MS film at -80oC before being
developed. Finally, the TLC plates were exposed to a phosphoimager screen
before being scanned and analyzed using ImageQuant TL software.

Plasmodium falciparum Cell-free Extract

Synchronized Plasmodium falciparum 3D7 cells were collected from
intraerythrocytic cultures as previously described and stored at -80oC until
needed. The pellet was then resuspended in a Lysis Buffer (20mM Tris-HCl
(pH8.0), 10mM EDTA, 800mM NaCl, 3% Triton X-100, 10mM NaF, and 10mM
β-Glycerophosphate) with protease inhibitors (Roche Mini Complete EDTAfree). Lysis of the cells was done by sonication and the cell lysate was clarified
by centrifugation at 14000rpm for twenty minutes at 4oC. The supernatant was
transferred to a clean microcentrifuge tube and the protein concentration was
determined by Bradford analysis (Bradford, 1979) using Protein Assay Reagent
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(BioRad) and varying concentrations of BSA (Sigma) as the protein standard
based on the expected sample concentration.

Generation of Polyclonal Antibodies

Initial Western blot analyses of the FIKK proteins were performed using
purified antibodies obtained from Sigma Genosys. The FIKK11 antibodies were
raised against the DELKDNIHSKNIYNC peptide. The peptides were emulsified
with Freund’s adjuvant and injected into rabbits (Freund, 1956; Freund and
McDermott, 1942). The animals were subjected to six injections before obtaining
the final bleed. For additional Western blot and immunofluorescence analyses,
purified chicken antibodies were obtained from Dr. Christian Doerig, a
collaborator in Glasgow, Scotland. The FIKK11 antibody was raised against the
RFTKEKSDVRNSDEF peptide corresponding to the C-terminal portion of the
protein. The secondary rabbit-α-chicken antibody was obtained from commercial
commercially sources (Jackson ImmunoResearch Labs).

SDS-PAGE and Transfer of Proteins to Nitrocellulose

Samples were resolved on SDS-PAGE as described by Ornstein and Davis
(Davis, 1964 and Ornstein, 1964). The samples were denatured by the addition of
4X SDS-PAGE Gel Loading Buffer (250mM Tris (pH 6.8), 8% SDS, 40%
Glycerol, and 20% β-Mercaptoethanol) to the protein samples and boiling the
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mixture for five minutes. The samples were resolved via a discontinuous buffer
system consisting of a stacking gel made with Tris-HCl (pH 6.8) on top of a
resolving gel made with Tris-HCl (pH 8.8), 10% Acrylamide, and a Tris-Glycine
buffer (pH 8.3). Pre-stained molecular weight marker (BioRad) was used as the
standard and the samples were run on the gel for ninety minutes at 150V. The gel
was removed and the proteins were electrophoretically transferred to
nitrocellulose membrane (Burnette, 1981 and Towbin, et al., 1979). The transfer
was performed for one hour at 100V.

Immunoblot Analysis

Immunoblot analysis was performed with polyclonal chicken and rabbit
antibodies. The nitrocellulose membrane was incubated in blocking solution (5%
milk in TBS-T) overnight at 4oC. The primary antibody was diluted (Table 3)
with 5% milk in TBS-T before incubation on the membrane for two hours at room
temperature. Unbound antibodies were removed by three 10 minute washes with
5% milk in TBS-T. The membrane was then incubated in the presence of diluted
(Table 3) secondary antibody for thirty minutes at room temperature.

The

membrane was then washed three times in TBS-T for 5 minutes each wash. Next,
the membrane was incubated in the dark in the presence of SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce) and subsequently exposed to film
(Classic Blue Sensitive, MidWest).
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Table 3. Antibody Dilutions for Western Blot Analysis
Antibody
Against:
FIKK11
Antibody
Against:
FIKK11

Rabbit
Antibody
1:3000
Chicken
Antibody
1:10000
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Secondary
Anti-Rabbit
1:5000
Secondary
Anti-Chicken
1:30000

Indirect Immunofluorescence Assay

Synchronous Plasmodium falciparum 3D7 was harvested from culture
plates and placed into a 15ml or 50ml conical tube depending on the amount of
culture collected. 500µl was transferred to a clean microcentrifuge tube and the
cells washed with 1X PBS. The cell suspension was centrifuged at 4000rpm for
one minute at 4oC and the supernatant was removed before being fixed in a 4%
Paraformaldehyde / 0.00075% Glutaraldehyde solution for thirty minutes. The
cells were then permeabilized by incubating them in 0.05% Triton X-100 for ten
minutes followed by a ten minute incubation in 0.1mg/ml NaBH4 to remove any
free aldehyde groups. Next, the cells were blocked in 3% BSA for one hour at
room temperature and incubated in the presence of primary antibody diluted
(Table 4) in 3% BSA overnight at 4oC. Three washes in 3% BSA removed any
unbound primary antibody and the cells were incubated for one hour in the
presence of secondary antibody diluted (Table 4) in 3% BSA in the dark at room
temperature. After a final PBS wash, 2µl of cells and 2µl of ToPro in Antifade
Agent were pooled onto a 12mm round coverslip pre-coated with 1%
Poly(ethyleneimine) solution. The mixture was incubated for twenty minutes at
room temperature and then the coverslips inverted onto a clean microscope slide
for viewing.
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Table 4. Antibody Dilutions for Immunofluorescence Assays

Antibody
Against
FIKK11

Chicken
Antibody
1:1000
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Secondary
Anti-Chicken
1:1000

CHAPTER THREE: RESULTS

Immunoblot Analysis of Stage-specific Plasmodium Extracts

Microarray analysis data obtained from PlasmoDB suggests that FIKK11
is mostly expressed in the schizont stage of the malaria life cycle with lower
expression occurring in the ring and trophozoite stages.

However, no

experimental evidence has yet been shown to support the expression of FIKK
family members at the protein level using Plamsodium falciparum cultures. To
verify the expression of FIKK11 by the parasite in vivo, we examined
synchronized Plasmodium cell-free extracts to ensure that each stage of the
parasite life cycle was represented. Fig. 4 shows a Gel Code Blue analysis of
malarial proteins as compared to uninfected red blood cells.

To verify that

FIKK11 is expressed in vivo, we performed a Western blot analysis using peptide
antibodies raised specifically against its catalytic domain. Our Western blot data
confirms that the expression of FIKK11 begins to increase in the late
trophozoite/early schizont stage and reaches a peak accumulation in the late
schizont stage of the parasite’s life cycle (Fig. 5). Furthermore, there isn’t any
indication of FIKK11 protein expression within the uninfected red blood cells
indicating a lack of cross-reactivity. This data confirms that FIKK11 is indeed
expressed within Plasmodium falciparum intraerythrocytic stages and supports the
microarray data showing its preferential expression in the schizont-stage.
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Figure 4. Gel Analysis of Uninfected Erythrocytes and Stage-Specific Malarial Extracts
Stage-specific extracts were harvested from synchronized Plasmodium
falciparum 3D7. 25ug of each sample were loaded onto 12.5% SDS-PAGE.
The gel was then stained using Gel Code Blue to resolve the proteins. Lane 1,
Uninfected Red Blood Cells; MW, Molecular Weight Marker; Lane 2, Ring;
Lane 3, early Trophozoite; Lane 4, Trophozoite; Lane 5, early Schizont; Lane 6,
Schizont; Lane 7, late Schizont.
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Figure 5. FIKK11 is Expressed Within All Stages of the Malaria Lifecycle

Stage-specific extracts were harvested from synchronized Plasmodium
falciparum 3D7. 25ug of each sample were loaded onto 12% SDS-PAGE
and the transferred to a nitrocellulose membrane. Chicken-raised FIKK11
antibodies were used as the primary antibody and commercially available
anti-chicken antibody was used as the secondary. The membrane was
exposed to film and developed to resolve the image. Lane 1, Uninfected Red
Blood Cells; MW, Molecular Weight Marker; Lane 2, Ring; Lane 3, early
Trophozoite; Lane 4, Trophozoite; Lane 5, early Schizont; Lane 6, Schizont;
Lane 7, late Schizont.
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Subcellular Localization of FIKK11 Using Immunofluorescence Imaging

Because of the presence of a double Host Targeting/Plasmodium Export
Element (HT/Pexel) in FIKK11, we were interested to analyze whether FIKK11
was indeed exported from the malarial parasite in vivo to a location within the
periphery of the parasite membrane or to the host erythrocyte. Using Plasmodium
falciparum-infected erythrocytes, we performed an immunofluorescence assay to
ascertain the localization of the protein. Fig. 6 shows the Differential Interference
Contrast (DIC) image and the immunofluorescence image of parasitized
erythrocytes. As can be seen from fig. 6, FIKK11 is localized in the erythrocyte
plasma membrane, parasitophorous vacuolar membrane, and unknown distinct
foci during the late ring/early trophozoite stages and not in the erythrocyte or
parasite cytosol. Our result is consistent with the fact that malarial proteins
containing the HT/Pexel motifs are targeted for export from the parasite (Hiller et
al., 2004; Marti et al., 2003). It has also been demonstrated that exported parasite
proteins often localize within intraerythrocytic structures called Maurer’s Clefts
(Stanley et al., 1989; Hinterberg et al., 1994). These will often appear as punctate
dots when viewed using an indirect immunofluroescence assay (Nunes et al.,
2006). Fig. 6 clearly shows a punctate appearance of FIKK11 suggesting a
possible association between it and the Maurer’s Clefts.

Additionally, the

fluorescence seen strongly suggests an association with the infected erythrocyte
membrane and possibly the parasitophorous vacuolar membrane.
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To verify that that FIKK11 expression was found within all stages of the
parasite life cycle beginning with the ring stage and increasing to Schizont stages
of the parasitic infection as is suggested by the immunoblot analysis, the
immunofluorescence assays were done with cells predominantly at those specific
stages of the cell cycle. Fig. 7 clearly demonstrates that the level of FIKK11
expression does increase in vivo at the Schizont stage of the parasite. This further
verifies the known microarray data for this protein as well as verifies the Western
blot analysis shown by our lab. Interestingly, fig. 7 shows the localization of
FIKK11 is restricted exclusively to the parasitophorous vacuolar membrane at the
Schizont stage.

This suggests a stage-dependent dynamics of FIKK11

localization in the intra-erythrocytic stages.
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Figure 6. FIKK11 is Localized within the Erythrocyte Membrane and Parasitophorous
Vacuolar Membrane in the Early Trophozoite Stage of the Malaria Lifecycle

Immunofluoresence was determined by fixing and permeabilizing cells prior to the
addition of a primary antibody raised against FIKK11 and the addition of Alexa Fluor
555 secondary antibody. This figure represents a cell as visualized using the Axiovert
100M confocal microscope. The upper left panel of each shows the DIC image of the cell
only. The lower left panel shows the immunofluorescence image of the FIKK11. The
larger panel represents the overlay of the DIC and immunofluorescence image.
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Figure 7. FIKK11 is Localized within the Parasitophorous Vacuolar Membrane at the
Schizont Stage of the Malaria Lifecycle
Immunofluoresence was determined by fixing and permeabilizing cells prior to
the addition of a primary antibody raised against FIKK11 and the addition of
Alexa Fluor 488 secondary antibody. This figure represents a cell as visualized
using the Axiovert 100M confocal microscope. The upper left panel of each
shows the DIC image of the cell only. The lower left panel shows the
immunofluorescence image of the FIKK11. The larger panel represents the
overlay of the DIC and immunofluorescence image.
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Cloning, Overexpression, and Purification of Malarial FIKK Kinases

Information gathered from the PlasmoDB database provided open-reading
frame sequences for many of the FIKK proteins.

We chose FIKK10.1 and

FIKK11 as candidates to study the catalytic properties of FIKK proteins (Fig. 8).
To establish whether these FIKKs function as protein kinases and for subsequent
functional analysis of these members of the FIKK kinase family, we amplified the
kinase domains of FIKK10.1 and FIKK11 by RT-PCR using mRNA isolated from
asynchronous 3D7 Plasmodium flaciparum parasites (fig. 9 and fig. 10). We
chose to amplify the kinase domains only because our initial attempts to express
full-length proteins containing the N-terminal secretory domain resulted in mostly
insoluble proteins. The amplification of the kinase domains, however, should be
sufficient to establish whether or not FIKK kinases are catalytically active. The
resulting amplified kinase domain sequences were verified by DNA sequencing
and were cloned into the T7 RNA polymerase-driven pET43.1 Ek/LIC vector.
Inserts for the open reading frames were verified after being released from the
pET43.1 vector by digestion with XbaI and XhoI (Fig. 11 and fig. 12). The
increase in size of the released inserts is due to the presence of the genes encoding
the Nus-His tag.

Cloning into this vector was accomplished by a ligation-

independent method that uses the 3’ → 5’ exonuclease activity of T4 DNA
polymerase to generate single-stranded nucleotide overhangs in the insert which
are complementary to a complementary overhang in the vector.

Following

annealing of the vector and insert, the reaction mixture was transformed into E.
36

coli Novablue supercompetent cells. This method is extremely efficient and most
of the resulting colonies contained the insert product.
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Figure 8. Comparative Sizes of the FIKK10.1 and FIKK11 Kinase Domain Sequences
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Figure 9. PCR Amplification of FIKK10.1 Kinase Domain
The Kinase domain of FIKK10.1 was amplified by RT-PCR.
product was resolved on 0.8% agarose gels using 1X TAE buffer.
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The PCR
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Figure 10. PCR Amplification of FIKK11 Kinase Domain
The Kinase domains of FIKK11 were amplified by RT-PCR.
product was resolved on 0.8% agarose gels using 1X TAE buffer.
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Figure 11. Verification of FIKK10.1 Kinase Domain Cloning into pET43 by Restriction
Enzyme Digestion
The PCR products were then cloned into the pET43LIC vector using a
ligation-independent cloning approach. Expression constructs were digested
with XbaI and XhoI to release the Nus-tagged insert and the restriction digest
was resolved on 0.8% agarose gels.
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3 kb2 kb1.5 kb-

Figure 12. Verificationof FIKK11 Kinase Domain Cloning into pET43 by Restriction
Enzyme Digestion
The PCR product was then cloned into the pET43LIC vector using a ligationindependent cloning approach. Expression constructs were digested with XbaI
and XhoI to release the Nus-tagged insert and the restriction digest was
resolved on 0.8% agarose gels.

MW
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Cells harboring the pET43.1-FIKK11 plasmid were induced with IPTG
and the cultures were then examined to determine the solubility of the proteins
from different fractions.

As was expected, SDS-PAGE analysis of induced

soluble and insoluble fractions showed the Nus-FIKK fusion proteins to be
present in the soluble fraction in sufficient amounts for subsequent purification
(Fig. 13).

43

100~95 kD
75-

50-

Figure 13. Induction of FIKK11 to Verify the Solubility of the Nus-tagged Fusion
Construct
BL21 (DE3) Codon+ E. coli cells were transformed with the FIKK11
recombinant protein and induced with 1mM IPTG at 27oC overnight. The
cells were then spun down and resuspended in a lysis buffer and sonicated for
6 cycles. The soluble and insoluble fractions were separated and the samples
run on SDS-PAGE gel. The final gel was stained with Gel Code Blue. MW,
molecular weight marker; Lane 1, uninduced; Lane 2, soluble fraction; Lane
3, insoluble fraction.
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The His-tagged recombinant FIKK fusion proteins were purified using a
TALON cobalt affinity chromatography (Clonetech) Clontech (Fig. 14). This
method uses Immobilized Metal Affinity Chromatography (IMAC) for separating
proteins through the interaction of a histidine amino acid tag with an immobilized
cobalt metal ion.

This can allow purification of proteins under native or

denaturing conditions and allows for elution of the bound, His-tagged protein
under relatively mild conditions. Fractions were examined to determine which
contained more of the recombinant FIKK proteins relative to other proteins.
Fractions enriched in recombinant FIKK were then concentrated and further
purified using a SuperDex 75 size exclusion chromatography for further
purification. Western blot analysis with His-tag antibodies confirmed the identity
of the purified recombinant FIKK11 (Fig. 15). The recombinant FIKK10.1 kinase
domain construct yielded similar results.
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Figure 14. TALON Purification of FIKK11
Using a TALON cobalt affinity purification column, 500µl samples were
collected and 20µl of each sample was run on SDS-PAGE gels. The gel was
subsequently stained with Gel Code Blue for visualization. MW, molecular
weight marker; Lanes 1-8, the eight fractions recovered during the TALON
purification of FIKK11. Fractions 3-5 were retained and used for further
enzymatic analysis.
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~95 kD

Figure 15. Verification of FIKK11 Recombinant Kinase Domain Purification by
Western-blot Analysis
The recombinant protein expression was induced by 1mM IPTG at 270C
overnight. Purification of the recombinant protein was achieved by using a
TALON cobalt affinty column (Clontech). The recombinant protein was
resolved on 8% SDS-PAGE. Lane 1 is a stained gel of the purified protein;
Lane 2 is a Western blot analysis of the recombinant protein using anti-His
antibodies.
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Characterization of Recombinant FIKK Protein Kinase Activity

The recombinant FIKK kinase domains of FIKK11 and FIKK10.1 were
assayed for either autophosphorylation, histone H1, myelin basic protein, or
dephosphorylated casein phosphorylation activity using a standard protein kinase
assay with ATP as the phosphodonor. The resulting reaction mixture was either
spotted on phosphocellulose filters ans analyzed using a Beckman scintillation
counter and/or run on SDS-PAGE gels for visualization by autoradiography.
None of the potential substrates used in the assay showed any phosphorylation by
the recombinant FIKK kinase domain proteins.

The recombinant FIKK10.1

kinase domain also showed negligable autophosphorylation activity, however, the
apparent autophosphorylation activity of the recombinant FIKK11 appeared to be
quite robust (Fig. 16). Interestingly, a significant mobility shift of the FIKK11
protein following autophosphorylation was also observed (Fig. 17).
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Figure 16. FIKK11 Recombinant Kinase Domain Shows Potential Autophosphorylation
Activity
Kinase activity of recombinant proteins were assessed in a reaction containing
50 mM Tris HCl, pH7.5, 10 mM MgCl2, 1 mM DTT, 40 mM b
glycerophosphate,100 µM sodium vanadate, 50 µM ATP, 1 µCi γ32P ATP, 0.5
µg enzyme in a 25 µl vol for 60 min at 30ºC. 10 µl samples were spotted on
P81 circles (Whatman) and 32P incorparation was quantitated following
phosphoric acid washes.
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Figure 17. Autoradiography Analysis of FIKK11 Recombinant Kinase Domain Shows a
Significant Mobility Shift
Kinase activity of recombinant proteins were assessed in a reaction
containing 50 mM Tris HCl, pH7.5, 10 mM MgCl2, 1 mM DTT, 40 mM b
glycerophosphate,100 µM sodium vanadate, 50 µM ATP, 1 µCi γ32P ATP,
0.5 µg enzyme in a 25 µl vol for 60 min at 30ºC. 20 µl reaction sample of
FIKK11 was resolved on a 10% SDS-PAGE. The autoradiograph was
exposed at -80ºC for 3 hours using Transcreen HE and BioMax MS film.
Lane 1, no enzyme; Lane 2, wild type protein.
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To determine whether FIKK11 required a specific bivalent-metal cofactor
to function properly, the recombinant FIKK11 protein was incubated in the
presence of protein kinase reaction mixtures containing various bivalent cations.
This assay showed that the recombinant FIKK11 kinase has an absolute
requirement for a free bivalent-metal cofactor, with Mg2+ being the preferred
cation. No significant catalytic activity was detected when Mn2+, Ca2+, or Zn2+
were substituted in the reaction mixture (Fig. 18).
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Figure 18. FIKK11 Activity is Dependent on Mg2+
Purified recombinant enzyme was incubated in a kinase reaction mixture
containing 10 mM of divalent cations.
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We examined the dependence of phosphorylation activity with increasing
enzyme concentration as well. Fig. 19 shows that the rate of the reaction is
roughly proportional to the amount of FIKK11 recombinant enzyme present.
About 6-7pmol of phosphate was incorporated per pmol of the enzyme.
To determine the reaction time for phosphorylation, kinase assays were
continued for different durations of time ranging from one minute to one hour
before stopping the reaction. As can be seen in fig. 20, recombinant FIKK11
activity was nearly linear with time beginning at 10min and showed no signs of
leveling off after even one hour of incubation.
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Figure 19. FIKK11 Activity Increases with Enzyme Concentration
0-10pmol of recombinant enzyme was incubated in a kinase reaction mixture
for 1hr at 30oC.
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Figure 20. FIKK11 Activity Increases with Incubation Time
4pmol of recombinant enzyme was incubated at 30oC using a kinase assay
system for 0-60 min.
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Because kinases are often characterized by their sensitivity to specific
diagnostic inhibitors, we tested the effect of a panel of inhibitors on the activity of
recombinant FIKK11. We used the following inhibitors: (a) Ro-31-8220, a
selective inhibitor for protein kinase C as well as MSK1, p90RSK, p70S6 kinase
1, and GSK3 (Davies et al., 2000: Deak et al., 1998), (b) KT 5720, a potent
inhibitor of protein kinase A, (c) genistein, an inhibitor of protein tyrosine kinases
(Hidaka and Kobayashi, 1993), and (d) staurosporine, a broad-spectrum inhibtor
of protein kinases. Only genistein and Ro-31-8220 showed significant inhibiton
(Fig. 21). Genistein (4,5,7-trihydroxyisoflavone) gave an IC50 of about 25µM
while Ro-31-8220 gave and IC50 of about 15µM.

Interestingly, the broad-

spectrum protein kinase inhibitor, staurosporine, which inhibits both Ser/Thr and
Tyr kinase is totally ineffective against recombinant FIKK11 even at 50µM. This
suggests that, although recombinant FIKK11 is inhibited by a Tyr kinase inhibitor
(genistein) and a PKC inhibitor (Ro-31-8220), it is refractory to staurosporine
which is an effective inhibitor of both Tyr kinases and PKC. This raises the
question of whether FIKK11 is a true protein kinase at all.

56

Genistein
Ro31-8220
KT 5720
Staurosporine

140

120

100

80

%Activity
60

40

20

0

0

5

50

500

5000

50000

Inhibitor Concentration (nM)

Figure 21. Effects of Protein Kinase Inhibitors on FIKK11 Activity
The inhibitors were added to a standard protein kinase assay at various
concentrations (5 nM-50 µM). Effects on protein phosphorylation were
analyzed by binding to phosphocellulose paper circles (P81).
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Determination of Plasmodium Protein Kinase Phosphorylation Specificity Using a
Positional Scanning Peptide Library

Recently, Dr. Benjamin Turk of Yale University developed a rapid method
to characterize eukaryotic protein kinase phsophorylation motifs using a
combinatorial peptide library.

This method systematically evaluates the

preference of a given kinase for every amino acid at each of nine sites
surrounding the phosphorylation site of a a given substrate (Hutti et al., 2004).
The method uses a library of roughly 200 distinct peptide mixtures each
containing a central fixed phosphorylation site flanked on either side by
degenerate positions.

For each of the nine positions surrounding the

phsophoacceptor site, twenty-two peptide mixtures are made in which each of the
twenty unmodified proteogenic amino acids as well as phosphothreonine and
phosphotyrosine are fixed. The entire collection consists of 198 peptides. These
peptide substrates are arrayed in a spatially addressable manner in a 384-well
plate and treated with the kinase of interest and radiolabeled ATP. Control
reactions are also run in the absence of peptide to determine the background from
kinase alone. At the end of the incubation time, aliquots of each reaction are
spotted simultaneously onto a streptavidin membrane using a capillary pin-based
liquid transfer device.

The membrane is immersed in a quenching solution,

washed extensively to remove unincorporated label, dried, and exposed to a
phspohor screen. This allows the amount of radiolabel incorporated into the
peptide to be quantified, providing an indication of which peptides are the most
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efficient substrates for a particular kinase. This in turn indicates which amino
acids at a particular position influence phosphorylation by that kinase. This
method has been used to profile over 50 serine-threonine and tyrosine kinses.
Fig. 22 shows a diagrammatical representation of how the positional scanning
peptide library works.
Because of the conflicting results observed when studying the
recombinant FIKK11 kinase, samples were sent to Dr. Turk’s lab to be assayed
for testing using the positional scanning peptide library. Peptide array substrate
analysis was not able to identify a single interacting peptide substrate for FIKK11.
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Figure 22. Peptide Array Method for Determining Protein Kinase Phosphorylation Motifs
For each of 9 positions surrounding the phosphorylation site, 22 peptides are synthesized
in which Z is fixed as one of the 20 unmodified proteogenic amino acids,
phosphothreonine or phosphotyrosine. X positions are equimolar mixtures of all residues
(excluding serine, threonine and cysteine).
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Analysis of Protein Kinase Assay Components

Since no interacting substrates were identified against recombinant
FIKK11, we began to suspect that our enzyme was phosphorylating some
component within our reaction mixture. To examine this possibility, reaction
mixtures were made in which one of the selected components was eliminated and
the protein kinase assay carried out as before in the presence of radiolabelled ATP.
Only the reaction mix lacking MgCl2 prevented the phosphorylation previously
seen from taking place (Fig. 23). This is expected since we had earlier shown that
MgCl2 is the preferred bivalent metal cation for this enzyme.
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Figure 23. Removal of MgCl2 from the Reaction Mixture Eliminated the Activity of
Recombinant FIKK11
Standard reaction mixes were made including several that lacked one of the
key components of the mixture. The reaction was carried out as before and
the resulting samples run on an SDS-PAGE gel and exposed to BioMax MS
film overnight to determine the results. Lane 1, no enzyme; Lane 2, enzyme
and standard reaction mix, Lane 3, reaction mix lacking MgCl2; Lane 4
reaction mix lacking DTT; Lane 5, reaction mix lacking β-glycerophosphate,
Lane 6, reaction mix lacking sodium vanadate.
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Glycerol had been used during purification of our protein to enhance the
stability of the recombinant FIKK11, a common practice during the purification
of proteins. Therefore, we decided to investigate the contribution of glycerol on
actual kinase activity to see if residual glycerol within the recombinant protein
samples is phosphorylated which is giving us the impression of FIKK11
autophosphorylation. To this end, a sample of recombinant FIKK11 protein was
purified without glycerol. When assayed using the protein kinase assay system,
the recombinant protein purified without glycerol showed no phosphorylation
compared with the recombinant protein purified with glycerol (Fig. 24). This
result may could be due to the fact that the protein is no longer active since the
stabilizing nature of the glycerol had been removed during its purification.
However, another possibility is that glycerol may actually be the substrate for the
recombinant FIKK11 protein.
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Figure 24. Removal of Glycerol During Protein Purification Eliminated Recombinant
FIKK11 Activity
Standard reaction mixes were used on recombinant FIKK proteins purified either
with or without the addition of glycerol and the reaction was carried out as before
and the resulting samples run on an SDS-PAGE gel and exposed to BioMax MS
film overnight to determine the results. Lane 1, no enzyme; Lane 2, enzyme
purified with glycerol; Lane 3, enzyme purified without glycerol.
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Characterization of Recombinant FIKK11 Glycerol Kinase Activity

Based on the observation that recombinant FIKK11 kinase showed no
activity at all when purified in the absence of glycerol, it is possible that the
enzyme is not a true protein kinase. This is even more likely given the fact that
FIKK11 lacks the traditional glycine triad common to most eukaryotic protein
kinases. To determine whether the recombinant FIKK11 kinase might have an
activity other than that of a protein kinase, the enzyme was assayed using glycerol
as a potential substrate. The recombinant FIKK11 kinase, however, showed no
significant glycerol kinase activity as compared to a commercially available
glycerol kinase (Fig. 25).
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Figure 25. FIKK11 Exhibits no Glycerol Kinase Activity
Glycerol kinase activity of FIKK11 was compared to a commercially available
glycerol kinase using a coupled reaction to measure the oxidation of NADH.
2.5mM ATP was incubated for five minutes in the presence of a reaction mixture
(0.05M Triethanolamine-HCl (pH 7.0), 2.5mM MgCl2, 20mM KCl, 0.1mM βMercaptoethanol, 0.2mM Phospho(enol)pyruvate, 0.2mM NADH, 2mM
Glycerol, 5U/ml Pyruvate Kinase, and 5U/ml Lactate Dehydrogenase). 100ng of
FIKK 11 or a commercially available E. coli glycerol kinase was added and the
activity measured over the course of 8 minutes using a Hewlett-Packard 8453
spectrophotometer to determine the decrease in absorbance of NADH at 340nm.
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Characterization of Recombinant FIKK11 Diacylgycerol Kinase Activity

Since our data showed conclusively that FIKK11 was not a glycerol
kinase, we tested the possibility whether the protein has any diacylglycerol kinase
activity.

To determine whether the recombinant FIKK11 kinase has

diacylglycerol

activity,

the

enzyme

was

assayed

using

1-Stearoyl-2-

arachindonoyl-sn-glycerol as a potential substrate. As evident in fig. 26, film
autoradiography analysis of the TLC plate shows that FIKK11 does exhibit
diacylglycerol kinase activity when compared to a commercially available DGK
and BSA and no enzyme used as negative controls. Additionally, quantification
by phosphoimage analysis of the radiolabelled spots shows that the recombinant
FIKK11 kinase has significant activity as a diacylglycerol kinase against 1,2-SAG
as a potential substrate. However, the activity is significantly less than that seen
using a commercially available diacylglycerol kinase (Fig. 27).
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Figure 26. Recombinant FIKK11 Exhibits Diacylglycerol Kinase Activity
DGK activity of recombinant proteins were assessed in a reaction containing 40mM
Bis-Tris (pH 7.5), 5mM MgCl2, 0.1mM EDTA, 1mM Spermine, 0.5mM DTT, 0.02%
Triton X-100, 1mM Sodium Desoxycholate, 250µM Cardiolipin, 500µM 1,2-SAG,
1mM ATP (with 5µCi γ32P ATP) and 1µg enzyme for 30 minutes at room temperature.
The reactions were spotted on TLC and then exposed at -800C for 30 minutes using
Transcreen HE and BioMax MS film.
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Figure 27. DGK Activity of Recombinant FIKK11 as Measured by Phosphoimaging
DGK activity of recombinant proteins were assessed in a reaction containing 40mM BisTris (pH 7.5), 5mM MgCl2, 0.1mM EDTA, 1mM Spermine, 0.5mM DTT, 0.02% Triton
X-100, 1mM Sodium Desoxycholate, 250µM Cardiolipin, 500µM 1,2-SAG, 1mM ATP
(with 5µCi γ32P ATP) and 1µg enzyme for 30 minutes at room temperature. The percent
activity for each reaction was measured on a phosphoimager after overnight exposure to a
phosphoimager cassette.
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CHAPTER FOUR: DISCUSSION

The identification of a novel family of FIKK kinases within the
Plasmodium flaciparum genome is a source of excitement for their potential as
targets for malaria therapy. However, little is actually known about the function
of these proteins. To this end, we decided to focus on the characterization of
several of these kinases in order to better understand their role and potential use as
drug targets.

Our studies focused on two objectives: (1) are these proteins

actually expressed by the malaria parasite and are they exported from the malaria
parasite into the erythrocyte cytoplasm or plasma membrane as is suggested by
their HT/Pexel motif and (2) are these proteins true protein kinases as is suggested
by sequence analysis?
Our first goal was to determine whether these proteins were in fact
expressed in vivo as has been suggested based on microarray studies.
Immunoblot analysis using mono-specific, affinity-purified antibodies raised
against FIKK11 confirms a stage-dependent expression of the protein in parasites
with a peak expression in the schixont stage. This results correlates well with the
microarray analysis gathered from Plasmo DB.
Since FIKK11 was shown to be present in vivo, we sought to determine
the localization of the protein within the parasite or host erythrocyte. Recent
evidence regarding the HT/Pexel motif found in malarial proteins suggests that
this motif is important in the export of those proteins into the erythrocyte cytosol
(Hiller et al., 2004; Marti et al., 2003). If the sequence seen in the FIKK11
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protein is a true HT/Pexel motif, then the same should be true for it. A recent
study that examined the localization of FIKK4.1 and FIKK12 (Nunes et al., 2007)
was able to show that those proteins were indeed exported from the parasite to a
location associated with the erythrocytes membrane. That same study, however,
also showed that FIKK9.2 was not exported beyond the parasite cell membrane
suggesting that not all of these FIKK proteins behave in the same manner. Using
an immunofluorescence assay, FIKK11 was clearly identified outside of the
parasite, within the host erythrocyte which is consistent with previous
observations for proteins containing the HT/Pexel motif. The distribution of
fluorescence within the infected erythrocytes strongly suggests an association
with the infected erythrocyte membrane and the parasitophorous vacuolar
membrane. It should be noted that significant localization of the FIKK11 protein
was detected on the erythrocyte membrane during the trophozoite stage of the
parasite life cycle. This may provide a basis for its role in antigenicty, something
characterized with the R45 protein (FIKK4.2) (Schneider and MercereauPuijalon, 2005). Additionally, the localization of FIKK11 appears to change with
the intra-erythrocytic maturation of the parasite and the expression of FIKK11
also clearly increases with age of the parasite confirming our immunoblot data.
Interestingly though, the expression of FIKK11 in the schizont stage appears to be
confined only to the parasitophorous vacuolar membrane.

This suggests a

dynamic expression of the protein based on the parasite developmental stages.
Although no direct evidence exists that the FIKK proteins alone are truly
protein kinases, we chose members of this family to create constructs for
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recombinant fusion proteins. It has been suggested that members of this family
are true protein kinases (Nunes et al., 2007), however the studies performed were
done using an in vivo pulldown followed by an in vitro kinase assay. The
problem with this approach is that the kinase activity detected in their studies
could have come from a contaminating or associated kinase rather than the
FIKK4.1 or FIKK12. Additionally, their studies only looked at FIKK4.1 and
FIKK12, so the assumption that all FIKK kinases are indeed protein kinases lacks
support.

Our initial protein kinase assays were performed with purified

recombinant protein and showed no phosphorylation of several standard protein
kinase substrates. However, there was significant activity using the recombinant
FIKK protein alone suggesting that there may be autophosphorylation. However,
the significant mobility shift and general smearing of the protein seen in the SDSPAGE gel strongly suggests an alternative explanation may be responsible for this
phenomena. It is possible that the presence of a pronounced mobility shift might
be due to the presence of something else co-purifying with the FIKK11.
To further examine the potential of FIKK11 as a protein kinase, inhibition
assays were performed on the recombinant FIKK11 protein but the results were
equally confusing. Our data showed that only Ro-31-8220, a protein kinase C
inhibitor, and genistein, a protein tyrosine kinase inhibitor, had any inhibitory
affect on the recombinant FIKK protein. However, staurosporine, which is a
broad-spectrum protein kinase inhibitor, had no affect on the activity of
recombinant FIKK11. KT 5720, an inhibitor of protein kinase A, also had no
affect on the recombinant FIKK protein. These discrepancies, along with the
72

smearing seen earlier, raise the possibility that FIKK11 is not a protein kinase
after all.
To confirm whether any protein kinase peptide substrate could be
identified for FIKK11, we sent the recombinant FIKK11 protein to Dr. Benjamin
Turk’s laboratory at Yale University for use in a phosphorylation assay using a
combinatorial peptide library. This method can quantify the amount of radiolabel
incorporated into a peptide and can indicate which amino acids at a particular
postion influence phosphorylation. His lab has successfully profiled over 50
serine-threonine and tyrosine kinases. Unfortunately, no peptide sequences were
identified to be substrates for FIKK11. The data collected also ruled out the
possibility that an autophopshorylation event may be occurring with FIKK11.
The inability of Dr. Turk’s laboratory to identify a single interacting substrate
from the peptide substrate arrays phosphorylated by eukaryotic protein kinases
caused us to consider other possibilities for FIKK11. Because of the general
kinase activity observed, it became apparent that the phosphorylation previously
observed was likely due to something within our protein kinase reaction mixture
that was reacting with the recombinant protein.
The use of glycerol in the purification of proteins is a common practice to
increase the stability of the protein that has been extracted. However, it might be
possible that residual glycerol from the purification remains in the protein sample
and the glycerol is the actual substrate for the recombinant FIKK11 protein. To
test this, additional recombinant FIKK11 was expressed and purified without the
use of glycerol. The recombinant FIKK proteins were then assayed using the
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same protein kinase assay system as before. Interestingly, the removal of glycerol
from the purification procedure caused the cessation of phosphoryation that had
been observed.
Based on observations that recombinant FIKK11 kinase showed no
activity at all when purified in the absence of glycerol, we began focusing on
FIKK11 as a glycerol kinase. This seemed likely given the fact that FIKK11
lacks the traditional glycine triad common to most eukaryotic protein kinases. To
this end, the recombinant FIKK11 protein was measured for glycerol kinase
activity. Glycerol kinases catalyze the transfer of a phosphoryl group from MgATP to glycerol to generate glycerol 3-phosphate and Mg-ADP (Lin, 1976).
Using a standard glycerol kinase assay which measures the oxidation of NADH
through a coupled reaction involving pyruvate kinase and lactate dehydrogenase
in intermediate steps, the activity of recombinant FIKK11 could be compared to a
commercially available glycerol kinase to assess its potential as a true glycerol
kinase. Unfortunately, spectrophotometric analysis of the recombinant protein
showed no glycerol kinase activity when compared to the positive control.
Having ruled out the possibility for FIKK11 to be a glycerol kinase, we
examined its potential role as a diacylglycerol kinase. Diacylglycerol kinases are
responsible for the phosphorylation of the second messenger diacylglycerol to
phosphatidic acid (Los et al., 2004).

This results in a recycling of

phosphatidylinositol 4,5-bisphosphate that serves as an intermediate in protein
kinase C-mediated signal transduction (Sakane et al., 1991; Goto and Kondo,
1993). This suggests that diacylglycerol kinases may serve to inhibit the activity
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of PKC by attenuating diacylglycerol levels (Shindo et al., 2003). The majority of
work regarding diacylglycerol kinases, however, has been done using mammalian
systems in which five different classes have been identified all of which possess
two or three cystein-rich domains labeled C1A, C1B, and C1C and a conserved
catalytic domain (Hurley et al., 1997). Unfortunately, there is relatively little
information available regarding the actual function of the many different
isozymes and their conserved domains (van Blitterswijk and Houssa, 2000; van
Blitterswijk and Houssa, 1999; Topham and Prescott, 2002). The amount of
variability within these classes makes finding a concrete common structure
difficult.

Many of these contain an EF-hand motif responsible for calcium

binding. This EF-hand motif and the typical cystein-rich domains are not present
in the FIKK11 kinase which may explain its preference for magnesium as a
cofactor. Indeed, recent studies involving plant diacylglycerol kinases have also
shown members that prefer magnesium instead of calcium (Gomez-Merino et al.,
2004).
Due to the fact that diacylglycerol kinases tend to be more heterogeneous
in their composition displaying a wide array of structures, it is be possible that the
recombinant FIKK11 is actually acting as a diacylglycerol kinase despite not
displaying the structure seen among the more widely studied mammalian
diacylglycerol kinases.

Using a diacylglycerol kinase assay system, the

recombinant protein was measured against several diacylglycerol substrates and
its activity compared to a commercially available diacyglycerol kinase.
Interestingly, the recombinant FIKK11 showed a fairly significant amount of
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activity with 1-stearoyl-2-arachidonoyl-sn-glycerol as a substrate when compared
to the same activity seen using negative controls, although it was substantially
less than the activity seen with the commercial diacylglycerol kinase. Based on
these results, coupled with the results from the protein kinase and glycerol kinase
assays, led to the conclusion that the recombinant FIKK11 kinase actually
possesses diacylglycerol kinase activity and not protein kinase activity as has
been recently speculated. The implications of these results are quite exciting
considering this would provide yet another potential target for signaling between
the host erythrocyte and the parasite and provides a new focus for future studies
considering no work to date has been done looking at the role of diacylglycerol
kinases within Plasmodium falciparum.
The study of this novel group of FIKK proteins within the Plasmodium
flaciparum genome focused on one protein in particular, FIKK11.

To

characterize its potential function, the recombinant protein was cloned, expressed,
and subjected to a series of kinase assays.

Although previous anaylsis has

suggested that this family may function as protein kinases, at least the
recombinant FIKK11 studied here appears to instead function as a diacylglycerol
kinase. The HT/Pexel motif of the protein does indeed appear to target the
protein for export from the parasite into the erythrocyte cytosol and beyond.
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